Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing

by

Investment in captive manufacturing capacity by bio/pharma companies is an indicator of the industry’s intentions with respect to outsourcing. Based on recent capital expenditure trends, it’s clear that bio/pharma companies would rather “make than buy.”

According to the latest PharmSource Trend Report, Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing, bio/pharma companies invested $118 billion in facilities and equipment during the 2010-2013 period, an amount at least 10 times greater than what CMOs have invested in themselves. Global and generic bio/pharma companies, in particular, have invested heavily in new capacity, especially for biopharmaceuticals and in emerging markets.

Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing analyzes recent trends in capital spending by bio/pharmaceutical companies and assesses the implications for the CMO industry. It tracks spending by…

More information on Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing is available here or by calling PharmSource at +1-703-383-4903.

Jim Miller is the founder and president of PharmSource Information Services, Inc. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the industry’s principal resource for serious consumers of information on contract drug development and manufacturing, PharmSource STRATEGIC ADVANTAGE. He is editor and publisher of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report.

More posts by Jim Miller